Moreover, it has been shown that the small molecule ionidamine directly targets ASC, disrupting its interaction with pro-caspase-1 and preventing inflammasome assembly in neuroinflammatory models, suggesting its potential applicability in IBD and PSC [181], but further studies are needed to evaluate the effects of these agents. Here, CASP1 is linked to inflammatory bowel disease.